Literature DB >> 11675353

Persistent preswitch clonotypic myeloma cells correlate with decreased survival: evidence for isotype switching within the myeloma clone.

T Reiman1, K Seeberger, B J Taylor, A J Szczepek, J Hanson, M J Mant, R W Coupland, A R Belch, L M Pilarski.   

Abstract

Multiple myeloma (MM) is identified by unique immunoglobulin heavy chain (IgH) variable diversity joining region gene rearrangements, termed clonotypic, and an M protein termed the "clinical" isotype. Transcripts encoding clonotypic pre and postswitch IgH isotypes were identified in MM peripheral blood mononuclear cells (PBMCs), bone marrow (BM), and mobilized blood. For 29 patients, 38 BM, 17 mobilized blood, and 334 sequential PBMC samples were analyzed at diagnosis, before and after transplantation for 2 to 107 months. The clinical clonotypic isotype was readily detectable and persisted throughout treatment. Eighty-two percent of BM and 38% of PBMC samples also expressed nonclinical clonotypic isotypes. Clonotypic immunoglobulin M (IgM) was detectable in 68% of BM and 25% of PBMC samples. Nonclinical clonotypic isotypes were detected in 41% of mobilized blood samples, but clonotypic IgM was detected in only 12%. Patients with persistent clonotypic IgM expression had adverse prognostic features at diagnosis (lower hemoglobin, higher beta(2)-microglobulin) and higher numbers of BM plasma cells compared with patients with infrequent/absent clonotypic IgM. Patients with persistent clonotypic IgM expression had significantly poorer survival than patients with infrequent IgM expression (P <.0001). In a multivariate analysis, persistent clonotypic IgM expression in the blood correlated independently with poor survival (P =.01). In nonobese diabetic severe combined immunodeficiency mice, xenografted MM cells expressed clinical and nonclinical postswitch clonotypic isotypes. MM expressing clonotypic IgM engrafted both primary and secondary mice, indicating their persistence within the murine BM. This study demonstrates that MM clonotypic cells expressing preswitch transcripts are tied to disease burden and outcomes. Because MM pathology involves postswitch plasma cells, this raises the possibility that IgH isotype switching in MM may accompany worsening disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675353     DOI: 10.1182/blood.v98.9.2791

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.

Authors:  Shmuel Yaccoby
Journal:  Clin Cancer Res       Date:  2005-11-01       Impact factor: 12.531

Review 2.  The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.

Authors:  Brian P O'Connor; Michael W Gleeson; Randolph J Noelle; Loren D Erickson
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

3.  Stemness of B-cell progenitors in multiple myeloma bone marrow.

Authors:  Kelly Boucher; Nancy Parquet; Raymond Widen; Kenneth Shain; Rachid Baz; Melissa Alsina; John Koomen; Claudio Anasetti; William Dalton; Lia E Perez
Journal:  Clin Cancer Res       Date:  2012-09-17       Impact factor: 12.531

4.  Nonirradiated NOD/SCID-human chimeric animal model for primary human multiple myeloma: a potential in vivo culture system.

Authors:  Shang-Yi Huang; Hwei-Fang Tien; Fang-Hsein Su; Su-Ming Hsu
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

5.  Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Tara M Tancred; Andrew R Belch; Tony Reiman; Linda M Pilarski; Julia Kirshner
Journal:  J Histochem Cytochem       Date:  2008-11-11       Impact factor: 2.479

6.  In multiple myeloma, bone-marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival.

Authors:  Carina S Debes Marun; Andrew R Belch; Linda M Pilarski
Journal:  Am J Hematol       Date:  2012-04-12       Impact factor: 10.047

7.  Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab.

Authors:  Linda M Pilarski; Eva Baigorri; Michael J Mant; Patrick M Pilarski; Penelope Adamson; Heddy Zola; Andrew R Belch
Journal:  Clin Med Oncol       Date:  2008-03-27

8.  In non-transplant patients with multiple myeloma, the pre-treatment level of clonotypic cells predicts event-free survival.

Authors:  Kyle J Thulien; Andrew R Belch; Tony Reiman; Linda M Pilarski
Journal:  Mol Cancer       Date:  2012-10-19       Impact factor: 27.401

9.  Frequent occurrence of highly expanded but unrelated B-cell clones in patients with multiple myeloma.

Authors:  Jitra Kriangkum; Sarah N Motz; Carina S Debes Marun; Sandrine T Lafarge; Spencer B Gibson; Christopher P Venner; James B Johnston; Andrew R Belch; Linda M Pilarski
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

10.  Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.

Authors:  Rakesh Bam; Sharmin Khan; Wen Ling; Shelton S Randal; Xin Li; Bart Barlogie; Ricky Edmondson; Shmuel Yaccoby
Journal:  BMC Cancer       Date:  2015-11-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.